Suchergebnisse - "Campbell, Christine"

PubPharm (8)

1

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Tutt, A. | Garber, J. | Kaufman, B. | +137

CommentIn: Nat Rev Clin Oncol. 2021 Oct;18(10):607-608. - PMID 34282304

2

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Moreno-Aspitia, A. | Holmes, E. | Jackisch, C. | +40

3

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer : exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

enthalten in: Breast cancer research and treatment | 2019

von Lambertini, M. | Campbell, C. | Gelber, R. | +15

4

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer : Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

enthalten in: Cancer | 2019

von Lambertini, M. | Martel, S. | Campbell, C. | +14

CommentIn: Cancer. 2019 Jan 15;125(2):181-184. - PMID 30500982

5

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

enthalten in: Journal of the National Cancer Institute | 2019

von Lambertini, M. | Campbell, C. | Bines, J. | +19

CommentIn: J Natl Cancer Inst. 2019 Jan 1;111(1):9-10. - PMID 29878141

6

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer : a NeoALTTO sub-study (BIG 1-06)

enthalten in: Breast cancer research and treatment | 2018

von Ponde, N. | Bradbury, I. | Lambertini, M. | +21

7

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

enthalten in: Journal of the National Cancer Institute | 2016

von Sonnenblick, A. | de Azambuja, E. | Agbor-Tarh, D. | +16

8

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab : A Secondary Analysis of the NeoALTTO Trial

enthalten in: JAMA oncology | 2015

von Salgado, R. | Denkert, C. | Campbell, C. | +13

CommentIn: JAMA Oncol. 2015 Jul;1(4):455-6. - PMID 26181253

1
[1]